Clinical Research Directory

Inclusion Criteria: * To participate in the study voluntarily and sign the informed consent (ICF), with good compliance and cooperative visits; * Patients must be ≥ 18 years of age (Based on the date of signing the informed Consent (ICF)); * Pathologically or Histologically confirmed NHL including but not limited to the following subtypes: 1. Follicular lymphoma (FL); 2. Chronic lymphocytic leukemia/small lymphocytic lymphoma or Richter syndrome (CLL/SLL or RS); 3. Marginal zone lymphoma (MZL); 4. Peripheral T-cell lymphoma (PTCL); 5. Diffuse large B-cell lymphoma (DLBCL). * Patients who have received at least one systemic chemotherapy and have relapsed at the end of the treatment or progressed during treatment; * Must have adequate organ function defined by the following laboratory parameters: 1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 0.5 × 10\^9/L, Platelet count (PLT) ≥ 25 × 10\^9/L, blood transfusion can be used before medication; 2. Liver and kidney function: Aspartate transaminase (AST) and alanine aminotransferase (ALT)≤5.0 × ULN; 3. Estimated creatinine clearance value ≥30 milliliters/minute (as determined by the Cockcroft-Gault method). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * Patients with infections should be treated first and then considered for enrollment when the infection is under control. Exclusion Criteria: * Female subjects who are pregnant or breastfeeding; * Estimated lifetime is less than 3 months; * In the investigator's judgment, patients who require but are unable to receive prophylactic treatment for Pneumocystis or herpes simplex virus (HSV) prior to trial drug treatment; * History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function; * Prior history of drug-induced colitis or drug-induced interstitial pneumonia; * Known hypersensitivity to Duvelisib or its excipients; * Administration of medications or foods that are strong inhibitors or inducers of CYP3A beginning 2 weeks prior to the first dose of Duvelisib; * According to the judgement of the researcher, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study.